NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis $17.40 -0.04 (-0.23%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$16.49▼$18.1350-Day Range$15.67▼$20.6652-Week Range$15.00▼$33.00Volume35,619 shsAverage Volume45,255 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$32.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Pharvaris alerts: Email Address Pharvaris MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside88.5% Upside$32.80 Price TargetShort InterestHealthy0.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.39) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector631st out of 936 stocksPharmaceutical Preparations Industry290th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePharvaris has only been the subject of 2 research reports in the past 90 days.Read more about Pharvaris' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.65% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently decreased by 9.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHVS. Previous Next 1.5 News and Social Media Coverage News SentimentPharvaris has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pharvaris this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Pharvaris' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pharvaris are expected to decrease in the coming year, from ($2.39) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -6.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -6.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pharvaris' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Pharvaris Stock (NASDAQ:PHVS)Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Read More PHVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHVS Stock News HeadlinesJuly 19, 2024 | uk.finance.yahoo.comPharvaris N.V. (9EN.SG)June 11, 2024 | globenewswire.comPharvaris Announces Annual Meeting of ShareholdersJuly 27, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 4, 2024 | globenewswire.comPharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent CongressesMay 13, 2024 | globenewswire.comPharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesMay 10, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | markets.businessinsider.comPharvaris’s Promising Drug Candidate Deucrictibant Bolsters Buy RatingMay 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Pharvaris (PHVS)July 27, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 9, 2024 | msn.comPHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024May 8, 2024 | globenewswire.comPharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 15, 2024 | markets.businessinsider.comPharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE TreatmentApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid FinancialsApril 12, 2024 | finance.yahoo.comPharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth PlansApril 12, 2024 | investing.comPharvaris appoints new CFO to bolster financial strategyApril 11, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial StabilityApril 11, 2024 | seekingalpha.comPHVS Pharvaris N.V.See More Headlines Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHVS CUSIPN/A CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$32.80 High Stock Price Target$50.00 Low Stock Price Target$11.00 Potential Upside/Downside+88.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.67% Return on Assets-37.38% Debt Debt-to-Equity RatioN/A Current Ratio20.52 Quick Ratio20.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book3.52Miscellaneous Outstanding Shares31,840,000Free FloatN/AMarket Cap$554.02 million OptionableNot Optionable Beta-3.10 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Berndt Axel Edvard Modig CPA (Age 65)M.B.A., Co-Founder, CEO & Executive Director Comp: $577.75kMs. Anna Nijdam M.Sc. (Age 43)R.A., Head of Strategic Finance & Principal Accounting Officer Dr. Stefan Abele Ph.D. (Age 54)Chief Technology Operations Officer Ms. Joan Schmidt J.D. (Age 60)Chief Legal Officer Ms. Annick Deschoolmeester (Age 51)Chief Human Resources Officer Dr. Peng Lu M.D. (Age 46)Ph.D., Chief Medical Officer Dr. Anne A. Lesage Ph.D. (Age 63)Chief Early Development Officer Dr. Morgan Conn Ph.D. (Age 55)Chief Business Officer Mr. Wim Souverijns Ph.D. (Age 53)Chief Commercial Officer Mr. David W. Nassif J.D. (Age 70)Chief Financial Officer More ExecutivesKey CompetitorsAesther Healthcare AcquisitionNASDAQ:AEHAWBioLingus (Cayman)NASDAQ:SUBLEvelo BiosciencesNASDAQ:EVLOGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXView All CompetitorsInstitutional OwnershipBain Capital Life Sciences Investors LLCSold 600,938 shares on 5/16/2024Ownership: 0.000%venBio Partners LLCSold 630,200 shares on 5/15/2024Ownership: 0.000%Price T Rowe Associates Inc. MDSold 84,783 shares on 5/15/2024Ownership: 0.000%View All Institutional Transactions PHVS Stock Analysis - Frequently Asked Questions How have PHVS shares performed this year? Pharvaris' stock was trading at $28.05 at the start of the year. Since then, PHVS stock has decreased by 38.0% and is now trading at $17.40. View the best growth stocks for 2024 here. How were Pharvaris' earnings last quarter? Pharvaris (NASDAQ:PHVS) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.56) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.56). When did Pharvaris IPO? Pharvaris (PHVS) raised $126 million in an IPO on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHVS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
